Effects of lower dose of imatinib to CML patients

Leukemia Research

Volumn 27, Issue 12, 2003, Pages 1167-

  Horikoshi, Akira ^a   Takei, Kazuhiro ^a   Sawada, Shigemasa ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR;

BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CYTOGENETICS; DRUG ACTIVITY; DRUG MARKETING; DRUG TOLERABILITY; EDEMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; RASH;

EID: 0042563130     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00101-2     Document Type: Letter

References (3)

1. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
2. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C.et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
3. Bakhtiar R., Lohne J., Ramos L., Khemani L., Hayes M., Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B. 768:2002;325-340.